Cedazuridine
Based on 1 publication(s) in Google Scholar
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research.
For research use only. We do not sell to patients.
- Purity: 99.72%
- CAS No.: 1141397-80-9
- Formula: C9H14F2N2O5
- Molecular Weight:268.21
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cedazuridine
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
IC50: 0.4 μM (CDA)[1]
Cedazuridine (Compound 7a) exhibits superior acid stability[1].
Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models[2]
-
Dosage:3 mg/kg
-
Administration:Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
-
Result:Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.
-
Animal Model:NSGS male mice[2]
-
Dosage:1, 3, 10 and 30 mg/kg
-
Administration:Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
-
Result:Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.
Chemical Information
-
CAS No. 1141397-80-9
-
Appearance Solid
-
Molecular Weight 268.21
-
Formula C9H14F2N2O5
-
Color White to off-white
-
SMILES
O[C@H]1C(F)(F)[C@H](N(CC[C@@H](O)N2)C2=O)O[C@@H]1CO
-
Synonyms
E7727
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res Commun
Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. [Abstract]2026 Mar 2. PMID: 41770597
Solvent & Solubility
DMSO : 116.67 mg/mL (434.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7284 mL | 18.6421 mL | 37.2842 mL | 93.2105 mL |
| 5 mM | 0.7457 mL | 3.7284 mL | 7.4568 mL | 18.6421 mL | |
| 10 mM | 0.3728 mL | 1.8642 mL | 3.7284 mL | 9.3211 mL | |
| 15 mM | 0.2486 mL | 1.2428 mL | 2.4856 mL | 6.2140 mL | |
| 20 mM | 0.1864 mL | 0.9321 mL | 1.8642 mL | 4.6605 mL | |
| 25 mM | 0.1491 mL | 0.7457 mL | 1.4914 mL | 3.7284 mL | |
| 30 mM | 0.1243 mL | 0.6214 mL | 1.2428 mL | 3.1070 mL | |
| 40 mM | 0.0932 mL | 0.4661 mL | 0.9321 mL | 2.3303 mL | |
| 50 mM | 0.0746 mL | 0.3728 mL | 0.7457 mL | 1.8642 mL | |
| 60 mM | 0.0621 mL | 0.3107 mL | 0.6214 mL | 1.5535 mL | |
| 80 mM | 0.0466 mL | 0.2330 mL | 0.4661 mL | 1.1651 mL | |
| 100 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.9321 mL |
Cedazuridine Related Classifications
HY-109081 Related Classifications
Powered by Bioz